The Cell and Gene Supply Chain Solutions segmentation by application distinguishes four primary revenue‑driving clusters. Therapeutic manufacturing encompasses upstream cell expansion, viral vector production, and downstream formulation, accounting for roughly 45 % of total market value because it captures the full‑scale commercial output of CAR‑T and gene‑editing therapies. Quality control & release covers analytical testing, sterility assurance, and batch release services, contributing about 25 % as regulators mandate stringent release criteria that generate recurring service contracts. Logistics & distribution includes temperature‑controlled transport, cold‑chain packaging, and last‑mile delivery, representing 20 % of the market; its share reflects the high‑cost, time‑sensitive nature of biologic shipments. Clinical trial support comprises investigational material handling, site‑level storage, and real‑time tracking for early‑phase studies, adding the remaining 10 % and acting as a growth engine for emerging pipelines. Collectively, these application segments map directly to the overall market size, with each proportion reflecting its relative capital intensity, regulatory burden, and frequency of repeat business.